Related Experiment Video
Updated: Sep 18, 2025
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
Jinpeng Cen1, Jiading Guo2, Xianzi Zeng3
1Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Introduction:
To investigate the molecular mechanisms underlying enzalutamide resistance in castration-resistant prostate cancer (CRPC) and explore potential therapeutic strategies to overcome resistance.
Methods:
We conducted comprehensive bioinformatic analysis using LNCaP/enzalutamide-resistant cells to identify key pathways associated with resistance. Functional validation was performed through targeted inhibition of the elongation of very-long chain fatty acid protein 2 (ELOVL2), followed by assays to assess cancer cell proliferation and enzalutamide sensitivity. Mechanistic studies were conducted to evaluate the impact of ELOVL2 on the ubiquitin-proteasome system and AR signaling pathways.
Results:
Bioinformatic analysis revealed that activation of fatty acid metabolism, particularly through upregulation of ELOVL2, plays a critical role in driving enzalutamide resistance in PCa. Functional studies demonstrated that targeted inhibition of ELOVL2 significantly suppressed cancer cell proliferation and restored enzalutamide sensitivity in resistant cells. Mechanistically, ELOVL2 facilitates enzalutamide resistance by impairing the ubiquitin-proteasome system, leading to the subsequent activation of AR signaling pathways.
Discussion:
Our findings demonstrate that ELOVL2 drives enzalutamide resistance in CRPC by stabilizing AR through inhibition of ubiquitin-proteasome-mediated degradation. Targeting ELOVL2 represents a promising therapeutic strategy to overcome resistance in CRPC, with potential to improve clinical outcomes for patients.
Insights
Targeting ELOVL2 overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC) by stabilizing androgen receptor (AR) signaling. Inhibiting ELOVL2 restores enzalutamide sensitivity, offering a new therapeutic strategy for CRPC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Enzalutamide resistance is a major challenge in treating castration-resistant prostate cancer (CRPC).
- Understanding the molecular mechanisms of resistance is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the molecular mechanisms of enzalutamide resistance in CRPC.
- To explore therapeutic strategies targeting these mechanisms, specifically focusing on ELOVL2.
Main Methods:
- Comprehensive bioinformatic analysis of LNCaP/enzalutamide-resistant cells.
- Functional validation through targeted inhibition of elongation of very-long chain fatty acid protein 2 (ELOVL2).
- Assessment of cancer cell proliferation, enzalutamide sensitivity, and impact on ubiquitin-proteasome system and AR signaling.
Main Results:
- Upregulation of ELOVL2 and activation of fatty acid metabolism are key drivers of enzalutamide resistance in prostate cancer (PCa).
- Targeted inhibition of ELOVL2 suppressed proliferation and restored sensitivity to enzalutamide in resistant cells.
- ELOVL2 impairs the ubiquitin-proteasome system, leading to AR signaling activation and enzalutamide resistance.
Conclusions:
- ELOVL2 promotes enzalutamide resistance in CRPC by stabilizing AR via inhibition of its degradation.
- Targeting ELOVL2 is a promising therapeutic strategy to overcome enzalutamide resistance in CRPC.
- This approach holds potential for improving clinical outcomes in CRPC patients.
Related Concept Videos
02:56Treatment Resistant Cancers
01:37The Unfolded Protein Response
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...